Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 5, 2017 - Issue 1
Journal homepage
931
Views
6
CrossRef citations to date
0
Altmetric
Original research article

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

Borislav BorissovPrescriptia EOOD, Sofia, BulgariaView further author information
,
Michael UrbichAmgen (Europe) GmbH, Economic Modeling Center of Excellence, Zug, SwitzerlandCorrespondence[email protected]
View further author information
,
Boryana GeorgievaAmgen Bulgaria EOOD, Value, Access & Policy, Sofia, BulgariaView further author information
,
Svetoslav TsenovAmgen Bulgaria EOOD, Value, Access & Policy, Sofia, BulgariaView further author information
&
Guillermo VillaAmgen (Europe) GmbH, Economic Modeling Center of Excellence, Zug, SwitzerlandView further author information
Article: 1412753 | Received 22 Sep 2017, Accepted 28 Nov 2017, Published online: 22 Dec 2017

Reprints and Permissions

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article in part or whole.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.